Klaus Kopka

Prof. Klaus Kopka

Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Saxony, Germany
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2016 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
CKClemens Kratochwil
Clemens Kratochwil
FBFrank Bruchertseifer
Frank Bruchertseifer
FGFrederik L. Giesel
Frederik L. Giesel
MWMirjam Weis
Mirjam Weis
FVFrederik A. Verburg
Frederik A. Verburg
AMAlfred Morgenstern
Alfred Morgenstern
Prostate specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently we started the first-in-man treatment with an alpha radionuclide labeled PSMA-ligand. While the case series is still ongoing, here we already report in advance about two patients with metastatic prostate cancer, progressive under multiple therapies and in highly challenging clinical situations, who showed complete responses to therapy with 225Ac-PSMA-617. Methods: 68Ga-PSMA-11 PET/CT validated a PSMA-positive tumor phenotype. Activities of 100 kBq/kg body-weight of 225Ac-PSMA-617 were administered bi-monthly. PSA response and hematological toxicity were measured at least every four weeks. Restaging was again performed with 68Ga-PSMA-11 PET/CT. Results: Both patients experienced a PSA decline below measurable and presented with complete imaging response. No relevant hematological toxicity was observed. Xerostomia was the only mentionable clinical side-effect. Conclusion: Targeted alpha therapy with 225Ac-PSMA-617, yet experimental, obviously offers a high potential to provide significant benefit to patients in critical condition, e. g. with diffuse red marrow infiltration and resistance against other therapies.

20 November 2014 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
AAAli Afshar-Oromieh
Ali Afshar-Oromieh
EAEleni Avtzi
Eleni Avtzi
Frederik L. GieselFrederik L. Giesel
Frederik L. Giesel
THTim Holland-Letz
Tim Holland-Letz
HLHeinz G. Linhart
Heinz G. Linhart
UHUwe Haberkorn
Uwe Haberkorn
Purpose Since the introduction of positron emission tomography (PET) imaging with 68Ga-PSMA-HBED-CC (=68Ga-DKFZ-PSMA-11), this method has been regarded as a significant step forward in the diagnosis of recurrent prostate cancer (PCa). However, published data exist for small patient cohorts only. The aim of this evaluation was to analyse the diagnostic value of 68Ga-PSMA-ligand PET/CT in a large cohort and the influence of several possibly interacting variables. Methods We performed a retrospective analysis in 319 patients who underwent 68Ga-PSMA-ligand PET/CT from 2011 to 2014. Potential influences of several factors such as prostate-specific antigen (PSA) level and doubling time (DT), Gleason score (GSC), androgen deprivation therapy (ADT), age and amount of injected tracer were evaluated. Histological verification was performed in 42 patients after the 68Ga-PSMA-ligand PET/CT. Tracer uptake was measured in 901 representative tumour lesions. Results In 82.8 % of the patients at least one lesion indicative of PCa was detected. Tumor-detection was positively associated with PSA level and ADT. GSC and PSA-DT were not associated with tumor-detection. The average maximum standardized uptake value (SUVmax) of tumour lesions was 13.3 ± 14.6 (0.7–122.5). Amongst lesions investigated by histology, 30 were false-negative in 4 different patients, and all other lesions (n = 416) were true-positive or true-negative. A lesion-based analysis of sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) revealed values of 76.6 %, 100 %, 91.4 % and 100 %. A patient-based analysis revealed a sensitivity of 88.1 %. Of 116 patients available for follow-up, 50 received local therapy after 68Ga-PSMA-ligand PET/CT. Conclusion 68Ga-PSMA-ligand PET/CT can detect recurrent PCa in a high number of patients. In addition, the radiotracer is highly specific for PCa. Tumour detection is positively associated with PSA and ADT. 68Ga-PSMA-ligand PET/CT can help delay systemic therapy of PCa.

10 March 2017 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
WFWolfgang P. Fendler
Wolfgang P. Fendler
MEMatthias Eiber
Matthias Eiber
MBMohsen Beheshti
Mohsen Beheshti
JBJamshed Bomanji
Jamshed Bomanji
Francesco CeciFrancesco Ceci
Francesco Ceci
KHKen Herrmann
Ken Herrmann

16 March 2016 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
CKClemens Kratochwil
Clemens Kratochwil
FGFrederik L. Giesel
Frederik L. Giesel
MSMelsa Stefanova
Melsa Stefanova
MBMartina Benešová
Martina Benešová
MBMarcus Bronzel
Marcus Bronzel
UHUwe Haberkorn
Uwe Haberkorn
Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). Besides high affinity and long tumor retention, the DOTA-conjugated ligand PSMA-617 has low kidney uptake making it an excellent choice for therapeutic application. We retrospectively report our experience with 177Lu-PSMA-617 targeted radionuclide therapy in a case series of mCRPC patients resistant to other treatments. Methods: Patients with PSMA-positive tumor phenotypes were selected by molecular imaging. 30 patients received 1-3 cycles of 177Lu-PSMA-617. During therapy pharmacokinetics and radiation-dosimetry were evaluated. Blood cell count was checked every two weeks after the first and every four weeks after succeeding cycles. PSA was determined every four weeks. Radiological restaging was performed after three cycles. Results: 21/30 patients had a PSA response; in 13/30 the PSA decreased >50%. After 3 cycles 8/11 patients achieved a sustained PSA response (>50%) for over 24 weeks which also correlated with radiological response (decreased lesion number and size). Normally, acute hematotoxicity was mild. Diffuse bone marrow involvement was a risk factor for higher grade myelosuppression but could be identified by PSMA-imaging in advance. Xerostomia, nausea and fatigue occurred sporadically (<10%). Clearance of non-tumor-bound tracer is predominantly renal and widely completed by 48h. Safety dosimetry reveals kidney doses of approx. 0.75 Gy/GBq, red-marrow 0.03 Gy/GBq, salivary glands 1.4 Gy/GBq; irrespective of tumor burden and consistent on subsequent cycles. Mean tumor absorbed dose ranged 6-22 Gy/GBq during cycle-1. Conclusion: 177Lu-PSMA-617 is a promising new option for therapy of mCRPC and deserves more attention in larger prospective trials.

16 April 2015 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
MBMartina Benešová
Martina Benešová
MSMartin Schäfer
Martin Schäfer
UBUlrike Bauder-Wüst
Ulrike Bauder-Wüst
AAAli Afshar-Oromieh
Ali Afshar-Oromieh
CKClemens Kratochwil
Clemens Kratochwil
MEMatthias Eder
Matthias Eder
Despite many advances in the past years, the treatment of metastatic prostate cancer still remains challenging. In recent years, prostate-specific membrane antigen (PSMA) inhibitors were intensively studied to develop low-molecular-weight ligands for imaging prostate cancer lesions by PET or SPECT. However, the endoradiotherapeutic use of these compounds requires optimization with regard to the radionuclide-chelating agent and the linker moiety between chelator and pharmacophore, which influence the overall pharmacokinetic properties of the resulting radioligand. In an effort to realize both detection and optimal treatment of prostate cancer, a tailor-made novel naphthyl-containing DOTA-conjugated PSMA inhibitor has been developed. Methods: The peptidomimetic structure was synthesized by solid-phase peptide chemistry and characterized using reversed-phase high-performance liquid chromatography and matrix-assisted laser desorption/ionization mass spectrometry. Subsequent 67/68Ga and 177Lu labeling resulted in radiochemical yields of greater than 97% or greater than 99%, respectively. Competitive binding and internalization experiments were performed using the PSMA-positive LNCaP cell line. The in vivo biodistribution and dynamic small-animal PET imaging studies were investigated in BALB/c nu/nu mice bearing LNCaP xenografts. Results: The chemically modified PSMA inhibitor PSMA-617 demonstrated high radiolytic stability for at least 72 h. A high inhibition potency (equilibrium dissociation constant [Ki] = 2.34 ± 2.94 nM on LNCaP; Ki = 0.37 ± 0.21 nM enzymatically determined) and highly efficient internalization into LNCaP cells were demonstrated. The small-animal PET measurements showed high tumor-to-background contrasts as early as 1 h after injection. Organ distribution revealed specific uptake in LNCaP tumors and in the kidneys 1 h after injection. With regard to therapeutic use, the compound exhibited a rapid clearance from the kidneys from 113.3 ± 24.4 at 1 h to 2.13 ± 1.36 percentage injected dose per gram at 24 h. The favorable pharmacokinetics of the molecule led to tumor-to-background ratios of 1,058 (tumor to blood) and 529 (tumor to muscle), respectively, 24 h after injection. Conclusion: The tailor-made DOTA-conjugated PSMA inhibitor PSMA-617 presented here is sustainably refined and advanced with respect to its tumor-targeting and pharmacokinetic properties by systematic chemical modification of the linker region. Therefore, this radiotracer is suitable for a first-in-human theranostic application and may help to improve the clinical management of prostate cancer in the future.

26 November 2016 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
Frederik L. GieselFrederik L. Giesel
Frederik L. Giesel
BHB. Hadaschik
B. Hadaschik
JCJens Cardinale
Jens Cardinale
JRJ. Radtke
J. Radtke
MVM. Vinsensia
M. Vinsensia
CKC. Kratochwil
C. Kratochwil
Purpose The prostate-specific membrane antigen (PSMA) targeted positron-emitting-tomography (PET) tracer 68Ga-PSMA-11 shows great promise in the detection of prostate cancer. However, 68Ga has several shortcomings as a radiolabel including short half-life and non-ideal energies, and this has motivated consideration of 18F-labelled analogs. 18F-PSMA-1007 was selected among several 18F-PSMA-ligand candidate compounds because it demonstrated high labelling yields, outstanding tumor uptake and fast, non-urinary background clearance. Here, we describe the properties of 18F-PSMA-1007 in human volunteers and patients. Methods Radiation dosimetry of 18F-PSMA-1007 was determined in three healthy volunteers who underwent whole-body PET-scans and concomitant blood and urine sampling. Following this, ten patients with high-risk prostate cancer underwent 18F-PSMA-1007 PET/CT (1 h and 3 h p.i.) and normal organ biodistribution and tumor uptakes were examined. Eight patients underwent prostatectomy with extended pelvic lymphadenectomy. Uptake in intra-prostatic lesions and lymph node metastases were correlated with final histopathology, including PSMA immunostaining. Results With an effective dose of approximately 4.4–5.5 mSv per 200–250 MBq examination, 18F-PSMA-1007 behaves similar to other PSMA-PET agents as well as to other 18F-labelled PET-tracers. In comparison to other PSMA-targeting PET-tracers, 18F-PSMA-1007 has reduced urinary clearance enabling excellent assessment of the prostate. Similar to 18F-DCFPyL and with slightly slower clearance kinetics than PSMA-11, favorable tumor-to-background ratios are observed 2–3 h after injection. In eight patients, diagnostic findings were successfully validated by histopathology. 18F-PSMA-1007 PET/CT detected 18 of 19 lymph node metastases in the pelvis, including nodes as small as 1 mm in diameter. Conclusion 18F-PSMA-1007 performs at least comparably to 68Ga-PSMA-11, but its longer half-life combined with its superior energy characteristics and non-urinary excretion overcomes some practical limitations of 68Ga-labelled PSMA-targeted tracers.